UNSPSC 51171704: Nifuroxazide

This classification denotes a topical anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PM5LI0P38J. European Medicines Agency schedules Nifuroxazide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09271MIG. Nifuroxazide generally arises in the molecular formula C12H9N3O5. The term NIFUROXAZIDE is an International Non-Proprietary Name or INN. NIFUROXAZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule nifuroxazide under HS 29321900 and SITC 51569. As of Q4 2014, NIFUROXAZIDE remains the US FDA Preferred Term for this commodity. Nifuroxazide bears US NLM identifiers UMLS ID C0068742 and NCI Concept Code C90982. SMILES: O1C(CCC1[N](=O)O)/C=N/NC(=O)C1CCC(O)CC1.

UNSPSC 51171704 Nifuroxazide, a Commodity code, does not align with the state and local procurement activity currently tagged under it. The single recent opportunity in the dataset — Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services — solicits laboratory testing infrastructure, staffing, and specimen handling rather than nifuroxazide as a pharmaceutical product. The scope covers immunoassay screening with LC/MS/MS or GC/MS confirmation, electronic result reporting, alternative testing methodologies including oral fluid and hair testing, and operation of an Interactive Voice Response system for randomized testing notifications across two collection sites in Plano and McKinney. This represents a services contract, not a procurement of the drug itself, indicating a mismatch between the code's nominal pharmaceutical scope and the actual work state and local jurisdictions are soliciting under this classification.

Collin County in Texas is the sole recent issuer identified under this code. The RFP 2026-327, due July 23, 2026, targets an estimated contract value of $600,000 over two years with three optional one-year renewal periods. Pricing is required on a per-test basis across three service models (screening only, confirmation after screening, and screening with automatic confirmation of positives), with annual testing demand projected at approximately 25,031 tests. The successful vendor must maintain lab certification from SAMHSA, TX DPS, or CAP, and evaluation combines a compliance review and detailed proposal assessment scored on vendor understanding (30 points), firm qualifications (25 points), client references (15 points), cost (30 points), and optional Phase 2 demonstrations (up to 30 points). The anticipated award date is August 10, 2026. This code shows limited recent state and local activity aligned with nifuroxazide procurement.